Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc plus optimized background therapy versus placebo plus optimized background therapy in antiretroviral-experienced HIV-1 patients with non-CCR5-tropic virus
2004-001779-20Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of maraviroc in Human immunodeficiency virus infection type 1 (3 arms), sponsored by Pfizer. Primary endpoint: Change from baseline to week 24 in plasma HIV-1 RNA. Started Oct 2004; status: completed.
02
Drugs
maraviroc
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2004-001779-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001779-20.